{"id":49968,"date":"2025-12-04T20:30:42","date_gmt":"2025-12-04T12:30:42","guid":{"rendered":"https:\/\/flcube.com\/?p=49968"},"modified":"2025-12-04T20:30:43","modified_gmt":"2025-12-04T12:30:43","slug":"sino-biopharm-tqf3250-glp-1-capsule-wins-fda-clinical-approval-for-weight-loss","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49968","title":{"rendered":"Sino-Biopharm TQF3250 GLP-1 Capsule Wins FDA Clinical Approval for Weight Loss"},"content":{"rendered":"\n<p><strong>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.<\/strong> (CTTQ), a core subsidiary of <strong>Sino Biopharmaceutical Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1177:HKG\">HKG: 1177<\/a>), announced that its Category\u202f1 candidate <strong>TQF3250 capsules<\/strong> has received <strong>FDA clinical approval<\/strong> for weight loss. The China NMPA accepted the clinical trial application for overweight\/obese patients in November, while the type\u202f2 diabetes trial was officially approved.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-development-status\">Regulatory Milestone &amp; Development Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Market<\/th><th>Status<\/th><th>Indication<\/th><th>Timeline<\/th><\/tr><\/thead><tbody><tr><td><strong>United States<\/strong><\/td><td>FDA clinical approval granted<\/td><td>Weight loss<\/td><td>Trial initiation Q1\u202f2026<\/td><\/tr><tr><td><strong>China<\/strong><\/td><td>NMPA application accepted (Nov\u202f2025)<\/td><td>Overweight\/obesity<\/td><td>Awaiting approval<\/td><\/tr><tr><td><strong>China<\/strong><\/td><td>NMPA clinical trial approved<\/td><td>Type\u202f2 diabetes<\/td><td>Recruitment ongoing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-tqf3250-mechanism-of-action\">Drug Profile: TQF3250 Mechanism of Action<\/h2>\n\n\n\n<p><strong>TQF3250<\/strong> is an <strong>oral small\u2011molecule biased GLP\u20111 receptor agonist (GLP\u20111RA)<\/strong> that selectively activates the <strong>cAMP\u2011biased GLP\u20111R signaling pathway<\/strong> while reducing <strong>\u03b2\u2011arrestin recruitment<\/strong> and receptor internalization, thereby:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prolonging duration of action<\/strong> compared to traditional GLP\u20111 drugs<\/li>\n\n\n\n<li><strong>Minimizing gastrointestinal side effects<\/strong> through biased signaling<\/li>\n\n\n\n<li><strong>Enhancing patient convenience<\/strong> via oral administration vs. injectable formulations<\/li>\n\n\n\n<li><strong>Improving long\u2011term treatment adherence<\/strong> with once\u2011daily dosing<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-advantages-amp-market-position\">Competitive Advantages &amp; Market Position<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>TQF3250<\/th><th>Traditional GLP\u20111 Drugs<\/th><\/tr><\/thead><tbody><tr><td><strong>Administration<\/strong><\/td><td>Oral capsule<\/td><td>Injectable<\/td><\/tr><tr><td><strong>Signaling Bias<\/strong><\/td><td>cAMP\u2011biased (reduced \u03b2\u2011arrestin)<\/td><td>Balanced signaling<\/td><\/tr><tr><td><strong>Side Effect Profile<\/strong><\/td><td>Reduced GI adverse events<\/td><td>Higher GI burden<\/td><\/tr><tr><td><strong>Patient Convenience<\/strong><\/td><td>High (no needles)<\/td><td>Moderate<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Small molecule<\/td><td>Peptide (injectable)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-strategic-outlook\">Market Context &amp; Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Obesity Market<\/strong>: China obesity population exceeds <strong>100 million<\/strong>; GLP\u20111 market projected <strong>\u00a530\u202fbillion<\/strong> by 2030<\/li>\n\n\n\n<li><strong>Diabetes Opportunity<\/strong>: Type\u202f2 diabetes market in China valued at <strong>\u00a550\u202fbillion<\/strong>, growing at <strong>8% CAGR<\/strong><\/li>\n\n\n\n<li><strong>Differentiation<\/strong>: First oral <strong>biased GLP\u20111 agonist<\/strong> to enter late\u2011stage development globally<\/li>\n\n\n\n<li><strong>Pipeline Value<\/strong>: CTTQ\u2019s oral formulation addresses key patient compliance barriers in GLP\u20111 therapy<\/li>\n\n\n\n<li><strong>Next Milestones<\/strong>: US Phase\u202fII initiation Q1\u202f2026; China Phase\u202fII obesity data expected H2\u202f2027<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding TQF3250 development timelines, clinical outcomes, and market potential. Actual results may differ due to clinical, regulatory, and competitive uncertainties.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a core subsidiary of Sino Biopharmaceutical Limited&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49969,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[661,62,39,908,4361,86,313],"class_list":["post-49968","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-chia-tai-tianqing-pharmaceutical","tag-clinical-trial-approval-initiation","tag-diabetes","tag-hkg-1177","tag-hot-targets","tag-obesity","tag-sino-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sino-Biopharm TQF3250 GLP-1 Capsule Wins FDA Clinical Approval for Weight Loss - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a core subsidiary of Sino Biopharmaceutical Limited (HKG: 1177), announced that its Category\u202f1 candidate TQF3250 capsules has received FDA clinical approval for weight loss. The China NMPA accepted the clinical trial application for overweight\/obese patients in November, while the type\u202f2 diabetes trial was officially approved.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49968\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sino-Biopharm TQF3250 GLP-1 Capsule Wins FDA Clinical Approval for Weight Loss\" \/>\n<meta property=\"og:description\" content=\"Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a core subsidiary of Sino Biopharmaceutical Limited (HKG: 1177), announced that its Category\u202f1 candidate TQF3250 capsules has received FDA clinical approval for weight loss. The China NMPA accepted the clinical trial application for overweight\/obese patients in November, while the type\u202f2 diabetes trial was officially approved.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49968\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-04T12:30:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-04T12:30:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0401-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49968#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49968\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sino-Biopharm TQF3250 GLP-1 Capsule Wins FDA Clinical Approval for Weight Loss\",\"datePublished\":\"2025-12-04T12:30:42+00:00\",\"dateModified\":\"2025-12-04T12:30:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49968\"},\"wordCount\":318,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49968#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0401-1.webp\",\"keywords\":[\"Chia Tai Tianqing Pharmaceutical\",\"Clinical trial approval \\\/ initiation\",\"Diabetes\",\"HKG: 1177\",\"Hot targets\",\"Obesity\",\"Sino Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49968#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49968\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49968\",\"name\":\"Sino-Biopharm TQF3250 GLP-1 Capsule Wins FDA Clinical Approval for Weight Loss - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49968#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49968#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0401-1.webp\",\"datePublished\":\"2025-12-04T12:30:42+00:00\",\"dateModified\":\"2025-12-04T12:30:43+00:00\",\"description\":\"Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a core subsidiary of Sino Biopharmaceutical Limited (HKG: 1177), announced that its Category\u202f1 candidate TQF3250 capsules has received FDA clinical approval for weight loss. The China NMPA accepted the clinical trial application for overweight\\\/obese patients in November, while the type\u202f2 diabetes trial was officially approved.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49968#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49968\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49968#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0401-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0401-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sino-Biopharm TQF3250 GLP-1 Capsule Wins FDA Clinical Approval for Weight Loss\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49968#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sino-Biopharm TQF3250 GLP-1 Capsule Wins FDA Clinical Approval for Weight Loss\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sino-Biopharm TQF3250 GLP-1 Capsule Wins FDA Clinical Approval for Weight Loss - Insight, China&#039;s Pharmaceutical Industry","description":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a core subsidiary of Sino Biopharmaceutical Limited (HKG: 1177), announced that its Category\u202f1 candidate TQF3250 capsules has received FDA clinical approval for weight loss. The China NMPA accepted the clinical trial application for overweight\/obese patients in November, while the type\u202f2 diabetes trial was officially approved.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49968","og_locale":"en_US","og_type":"article","og_title":"Sino-Biopharm TQF3250 GLP-1 Capsule Wins FDA Clinical Approval for Weight Loss","og_description":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a core subsidiary of Sino Biopharmaceutical Limited (HKG: 1177), announced that its Category\u202f1 candidate TQF3250 capsules has received FDA clinical approval for weight loss. The China NMPA accepted the clinical trial application for overweight\/obese patients in November, while the type\u202f2 diabetes trial was officially approved.","og_url":"https:\/\/flcube.com\/?p=49968","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-04T12:30:42+00:00","article_modified_time":"2025-12-04T12:30:43+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0401-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49968#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49968"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sino-Biopharm TQF3250 GLP-1 Capsule Wins FDA Clinical Approval for Weight Loss","datePublished":"2025-12-04T12:30:42+00:00","dateModified":"2025-12-04T12:30:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49968"},"wordCount":318,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49968#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0401-1.webp","keywords":["Chia Tai Tianqing Pharmaceutical","Clinical trial approval \/ initiation","Diabetes","HKG: 1177","Hot targets","Obesity","Sino Biopharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49968#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49968","url":"https:\/\/flcube.com\/?p=49968","name":"Sino-Biopharm TQF3250 GLP-1 Capsule Wins FDA Clinical Approval for Weight Loss - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49968#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49968#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0401-1.webp","datePublished":"2025-12-04T12:30:42+00:00","dateModified":"2025-12-04T12:30:43+00:00","description":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a core subsidiary of Sino Biopharmaceutical Limited (HKG: 1177), announced that its Category\u202f1 candidate TQF3250 capsules has received FDA clinical approval for weight loss. The China NMPA accepted the clinical trial application for overweight\/obese patients in November, while the type\u202f2 diabetes trial was officially approved.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49968#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49968"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49968#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0401-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0401-1.webp","width":1080,"height":608,"caption":"Sino-Biopharm TQF3250 GLP-1 Capsule Wins FDA Clinical Approval for Weight Loss"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49968#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sino-Biopharm TQF3250 GLP-1 Capsule Wins FDA Clinical Approval for Weight Loss"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0401-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49968","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49968"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49968\/revisions"}],"predecessor-version":[{"id":49970,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49968\/revisions\/49970"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49969"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49968"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49968"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49968"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}